Review
Version 6
Preserved in Portico This version is not peer-reviewed
Convalescent Plasma Therapy for Covid-19: State of the Art
Version 1
: Received: 6 April 2020 / Approved: 7 April 2020 / Online: 7 April 2020 (11:47:15 CEST)
Version 2 : Received: 8 April 2020 / Approved: 8 April 2020 / Online: 8 April 2020 (11:43:14 CEST)
Version 3 : Received: 11 April 2020 / Approved: 13 April 2020 / Online: 13 April 2020 (10:56:12 CEST)
Version 4 : Received: 20 April 2020 / Approved: 22 April 2020 / Online: 22 April 2020 (09:50:33 CEST)
Version 5 : Received: 27 April 2020 / Approved: 28 April 2020 / Online: 28 April 2020 (09:37:10 CEST)
Version 6 : Received: 27 May 2020 / Approved: 28 May 2020 / Online: 28 May 2020 (11:52:38 CEST)
Version 7 : Received: 1 July 2020 / Approved: 1 July 2020 / Online: 1 July 2020 (14:12:21 CEST)
Version 2 : Received: 8 April 2020 / Approved: 8 April 2020 / Online: 8 April 2020 (11:43:14 CEST)
Version 3 : Received: 11 April 2020 / Approved: 13 April 2020 / Online: 13 April 2020 (10:56:12 CEST)
Version 4 : Received: 20 April 2020 / Approved: 22 April 2020 / Online: 22 April 2020 (09:50:33 CEST)
Version 5 : Received: 27 April 2020 / Approved: 28 April 2020 / Online: 28 April 2020 (09:37:10 CEST)
Version 6 : Received: 27 May 2020 / Approved: 28 May 2020 / Online: 28 May 2020 (11:52:38 CEST)
Version 7 : Received: 1 July 2020 / Approved: 1 July 2020 / Online: 1 July 2020 (14:12:21 CEST)
How to cite: Focosi, D.; Tang, J.; Anderson, A.; Tuccori, M. Convalescent Plasma Therapy for Covid-19: State of the Art. Preprints 2020, 2020040097. https://doi.org/10.20944/preprints202004.0097.v6 Focosi, D.; Tang, J.; Anderson, A.; Tuccori, M. Convalescent Plasma Therapy for Covid-19: State of the Art. Preprints 2020, 2020040097. https://doi.org/10.20944/preprints202004.0097.v6
Abstract
Convalescent blood product therapy has been introduced since early 1900s to treat emerging infectious disease based on the evidence that polyclonal neutralizing antibodies can reduce duration of viremia. Recent large outbreaks of viral diseases for whom effective antivirals or vaccines are still lacking has revamped the interest in convalescent plasma as life-saving treatments. This review summarizes historical settings of application, and surveys current technologies for collection, manufacturing, pathogen inactivation, and banking, with a focus on COVID-19.
Keywords
convalescent plasma; serology; pathogen reduction technologies; pathogen inactivation; COVID-19; SARS-CoV2
Subject
Biology and Life Sciences, Immunology and Microbiology
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (2)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment
Commenter: Daniele Focosi
Commenter's Conflict of Interests: Author
Commenter: David H. Muljono
The commenter has declared there is no conflict of interests.
The authors describe their concern on TRALI, which can be life-threatening in donors receiving plasma transfusion for women who have been sensitized to fetal protein. This necessitates the screening for anti-HLA/HNA/HPA antibodies to prevent TRALI.
The European Commission mentions the need to test the three antibodies in the document '''An EU programme of COVID-19 convalescent plasma collection and transfusion", but not specifically refers to TRALI.
Anti-HLA and anti-HNA have been largely discussed with regard to their association with TRALI, However, anti-HPA is more related to purpura instead of TRALI in many publications. Could you add references regarding its relatedness with TRALI.
Thank you
David h. Muljono